[ATRS] Antares Pharma, Inc.


Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 2.38 Change: 0.16 (7.21%)
Ext. hours: Change: 0 (0%)

chart ATRS

Refresh chart

Strongest Trends Summary For ATRS

ATRS is in the long-term up 97% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company?s injection products include OTREXUP, a pre-filled methotrexate syringe with Medi-Jet technology to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Tjet/Zomajet, the needle-free auto injectors to deliver human growth hormone treatment to children without the use of a needle. Its transdermal products comprise Gelnique3%, an oxybutynin gel product for the treatment of overactive bladder; and Elestrin, a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. The company is also developing OTREXUP for the treatment poly-articular-course juvenile RA and psoriasis; Vibex QS T for testosterone replacement therapy for men suffering from symptomatic testosterone deficiency; Vibex auto injectors; and disposable

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.14 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 31.94% Sales Growth - Q/Q-0.64% P/E-20.71
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-56.49% ROE-94.3% ROI
Current Ratio1.97 Quick Ratio1.69 Long Term Debt/Equity Debt Ratio0.6
Gross Margin53.67% Operating Margin-111.47% Net Profit Margin-111.8% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-10 K Cash From Investing Activities180 K Cash From Operating Activities-10.66 M Gross Profit4.67 M
Net Profit-6.79 M Operating Profit-6.74 M Total Assets58.67 M Total Current Assets41.36 M
Total Current Liabilities21.05 M Total Debt Total Liabilities23.52 M Total Revenue8.35 M
Technical Data
High 52 week3.89 Low 52 week2.36 Last close2.81 Last change-1.4%
RSI49.45 Average true range0.14 Beta0.72 Volume2 M
Simple moving average 20 days-1.77% Simple moving average 50 days-6.77% Simple moving average 200 days-12.28%
Performance Data
Performance Week-3.44% Performance Month3.69% Performance Quart-12.19% Performance Half-15.36%
Performance Year9.34% Performance Year-to-date3.31% Volatility daily2.84% Volatility weekly6.35%
Volatility monthly13.01% Volatility yearly45.07% Relative Volume377.1% Average Volume1.15 M
New High2.16% New Low


2019-11-13 07:00:00 | Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference

2019-11-09 08:19:55 | Edited Transcript of ATRS earnings conference call or presentation 5-Nov-19 1:30pm GMT

2019-11-05 07:00:00 | Antares Pharma Reports Third Quarter 2019 Operating and Financial Results

2019-11-01 11:49:48 | Hedge Funds Are Selling Antares Pharma Inc ATRS

2019-10-31 07:00:05 | Antares Pharma Announces Receipt of Final Payment From Sale of Zomajet™ Needle-Free Delivery System

2019-10-29 07:00:05 | Antares Pharma to Report Third Quarter 2019 Financial and Operating Results

2019-10-24 07:00:05 | Antares Pharma Announces Two Poster Presentations at the 2019 Sexual Medicine Society Scientific Annual Meeting

2019-10-17 06:55:37 | Do Directors Own Antares Pharma, Inc. NASDAQ:ATRS Shares?

2019-09-17 07:00:00 | Antares Pharma to Present at the Ladenburg Thalmann 2019 Healthcare Conference

2019-09-11 11:50:49 | Does Antares Pharma NASDAQ:ATRS Have A Healthy Balance Sheet?

2019-08-20 08:09:00 | Teva says FDA-approved generic EpiPen is now available in the U.S. for $300 for a 2-pack

2019-08-07 00:30:36 | Edited Transcript of ATRS earnings conference call or presentation 6-Aug-19 12:30pm GMT

2019-08-06 17:23:34 | Antares Pharma Inc ATRS Q2 2019 Earnings Call Transcript

2019-08-06 15:00:44 | Loss-Making Antares Pharma, Inc. NASDAQ:ATRS Expected To Breakeven

2019-08-06 07:00:00 | Antares Pharma Reports Second Quarter 2019 Operating and Financial Results

2019-07-30 07:00:00 | Antares Pharma to Report Second Quarter 2019 Financial and Operating Results

2019-06-27 07:00:00 | Antares Pharma Announces Amendment to Existing Loan and Security Agreement With Hercules Capital

2019-06-26 14:08:45 | Here is What Hedge Funds Think About Antares Pharma Inc ATRS

2019-06-11 07:00:00 | Antares Pharma to Present at the Raymond James 2019 Life Sciences and MedTech Conference

2019-06-06 11:45:34 | Have Insiders Been Selling Antares Pharma, Inc. NASDAQ:ATRS Shares This Year?

2019-05-30 07:00:00 | Antares Pharma to Present at the Jefferies 2019 Healthcare Conference

2019-05-16 17:00:00 | Antares Pharma to Present at the B. Riley FBR Institutional Investor Conference

2019-05-09 14:23:21 | Investors Who Bought Antares Pharma NASDAQ:ATRS Shares Three Years Ago Are Now Up 265%

2019-05-02 21:30:31 | Edited Transcript of ATRS earnings conference call or presentation 2-May-19 12:30pm GMT

2019-05-02 13:49:06 | Antares Pharma Inc ATRS Q1 2019 Earnings Call Transcript

2019-05-02 09:01:47 | Antares Pharma: 1Q Earnings Snapshot

2019-05-02 07:00:00 | Antares Pharma Reports First Quarter 2019 Operating and Financial Results

2019-04-18 07:00:00 | Antares Pharma to Report First Quarter 2019 Financial and Operating Results

2019-04-02 09:43:49 | Why Antares Pharma, Inc.'s NASDAQ:ATRS CEO Pay Matters To You

2019-04-01 07:30:00 | New Research: Key Drivers of Growth for Progress Software, Antares Pharma, National Vision, NMI, Waters, and Kelly Services — Factors of Influence, Major Initiatives and Sustained Production

2019-03-28 07:30:00 | Antares Pharma Announces Receipt of Orphan Drug Designation for the Treatment of Ectopic Pregnancy With Methotrexate

2019-03-15 15:43:51 | Edited Transcript of ATRS earnings conference call or presentation 28-Feb-19 1:30pm GMT

2019-03-12 18:48:10 | Antares Pharma Inc ATRS Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-03-11 10:35:02 | AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study

2019-03-06 07:00:00 | Antares Pharma to Present at the Cowen and Company 39th Annual Healthcare Conference

2019-03-04 07:00:00 | Antares Pharma Appoints Dr. Karen Smith to Board of Directors and Announces Retirement of Dr. Jacques Gonella

2019-02-28 12:31:49 | Antares Pharma Inc ATRS Q4 2018 Earnings Conference Call Transcript

2019-02-28 07:00:00 | Antares Pharma Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

2019-02-27 07:00:00 | Antares Pharma to Present at the Raymond James & Associates 40th Annual Institutional Investors Conference

2019-02-25 17:00:00 | Antares Pharma to Report Fourth Quarter and Full Year 2018 Financial and Operating Results

2019-01-20 09:49:20 | Antares Pharma, Inc. NASDAQ:ATRS: Time For A Financial Health Check

2018-12-13 10:32:03 | What Kind Of Shareholder Appears On The Antares Pharma, Inc.’s NASDAQ:ATRS Shareholder Register?

2018-12-13 07:00:00 | Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors

2018-12-10 09:45:00 | ATRS: Xyosted & Epi Pen Available for Sale

2018-12-07 01:35:33 | Should You Buy NanoString Technologies Inc NSTG?

2018-12-05 17:09:43 | Is Noodles & Co NDLS A Good Stock To Buy?

2018-12-03 08:15:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Antares Pharma, Encana, PPG Industries, Cato, Cimarex Energy, and Ormat Technologies — New Research Emphasizes Economic Growth

2018-11-29 07:00:00 | Antares Pharma Announces the Commercial Availability of XYOSTED™ Testosterone Enanthate Injection — A New Treatment for Adult Men Diagnosed With Testosterone Deficiency

2018-11-28 08:39:01 | Teva TEVA Launches First Generic Version of Mylan's EpiPen

2018-11-27 13:47:28 | Teva's generic EpiPen hits the market in limited doses